Install
Research & Evidence
Trial design, systematic reviews, medical statistics, and guideline updates.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Research & Evidence
Targeted Radionuclide Therapy Moves Earlier Across the Cancer Treatment Continuum
3+ hour, 33+ min ago (260+ words) Scott Tagawa, MD, Weill Cornell Medicine, New York, New York, discusses the evolving role of targeted radionuclide therapy and theranostics in oncology, including how diagnostic imaging can help identify patients most likely to benefit from treatment. Hi, my name is…...
New therapy moves closer to Phase 2 testing in progressive MS
16+ hour, 32+ min ago (481+ words) Thermo Fisher will support study start-up after FDA clearance to proceed Written by Andrea Lobo, PhD | Oct. 8, 2026 Quantum Biopharma is working with Thermo Fisher Scientific to prepare a Phase 2 trial of Lucid-MS in people with progressive multiple sclerosis. (Image from…...
Natural Killer Cell Lymphoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
11+ hour, 32+ min ago (93+ words) The Natural Killer Cell Lymphoma clinical trial analysis report delivers important insights into ongoing research on 100 pipeline Natural Killer Cell Lymphoma Drugs clinical strategies upcoming therapeutics and commercial analysis Albany US On October 08 2026 DelveInsight s Natural Killer... Natural Killer Cell…...
LTR Pharma Brings Roxus® Intranasal Vardenafil to U.S. Prescribers: Peak Plasma Levels in a Median of 10 Minutes
17+ hour, 3+ min ago (317+ words) Oct 08, 2026, 10:00 ET An estimated 30 to 35 percent of men do not respond adequately to oral PDE5 inhibitors,¹ and oral tablets ask every patient to plan intimacy around absorption time and meals. Roxus takes a different approach to both: a different route of…...
Endeavor BioMedicines' WHISTLE-PF Phase 2b Trial of Taladegib Meets Primary and Key Secondary Endpoints in Patients With IPF
13+ hour, 31+ min ago (324+ words) The trial demonstrated statistical significance for multiple secondary endpoints compared to placebo, including reduced lung fibrosis and increased total lung capacity (TLC) as shown by key measures on quantitative high-resolution computed tomography (HRCT) imaging Patients treated with taladegib experienced an…...
BlackDoctor Launches Medical Advisory Board With 8 Physicians
11+ hour, 7+ min ago (246+ words) The Black-owned health platform is adding clinical oversight as it expands services for more than 30 million users. BlackDoctor is backing its digital health ambitions with more clinical expertise. The new advisory board will help shape the company’s clinical strategy, product…...
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
9+ hour, 40+ min ago (243+ words) The Manila Times Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA) Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the…...
Stanford's TCIP3 wipes out lymphoma tumors in 11 days
19+ hour, 58+ min ago (77+ words) | Tap to know more | Inshorts Inshorts Stanford's TCIP3 wipes out lymphoma tumors in 11 days Stanford researchers developed TCIP3, a compound that repurposes cancer-driving protein BCL6 to trigger cancer cell death instead of blocking it. In mouse studies, tumors vanished within 11 days. Unlike current…...
Carotuximab/Apalutamide Further Extends PFS in Metastatic CRPC
10+ hour, 18+ min ago (441+ words) Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC. Carotuximab (ENV-105) plus apalutamide (Erleada) produced a statistically significant improvement in progression-free survival (PFS) vs apalutamide alone in patients…...
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
11+ hour, 4+ min ago (47+ words) Edgewise Therapeutics could benefit from EDG-7500's differentiated drug profile, a potentially lighter phase 3 monitoring approach and possible validation from rival studies, though elevated... Biotechnology & Medical Research Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says Published on 09/25/2026 at…...